Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on May 22, 2025
Press release: Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
GlobeNewswire
·
May 22, 2025
Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders Ghent, Belgium, 22 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant …
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire
·
May 22, 2025
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a …
Nisa Foundation’s Brand New Transition House Offers Greater Support and Culturally-Responsive Care for Women and Children Fleeing Violence
GlobeNewswire
·
May 22, 2025
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- In partnership with BC Housing, Nisa Foundation is proud to announce the expansion of Nisa Homes Vancouver, with a brand new location now operating as a 24/7 transition house with double the …
Bio Usawa and Pacific Environmental Technologies Announce Landmark Partnership to Develop and Deploy Modular cGMP Biomanufacturing Units for Africa
GlobeNewswire
·
May 22, 2025
SAN FRANCISCO and KIGALI, Rwanda, May 22, 2025 (GLOBE NEWSWIRE) -- Bio Usawa, Inc., a biopharmaceutical company based in San Francisco, Kigali, and Nairobi, committed to expanding access to life-saving biologics in Africa and underserved regions, today …
Total Ancillary Joins Forces with WoundGenex
GlobeNewswire
·
May 22, 2025
DALLAS, May 22, 2025 (GLOBE NEWSWIRE) -- Providers now will have access to additional support services, thanks to an alliance between leading wound care solutions provider Total Ancillary and WoundGenex, a trusted name in wound care associated …
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene
GlobeNewswire
·
May 22, 2025
MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as …
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GlobeNewswire
·
May 22, 2025
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, …
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
GlobeNewswire
·
May 22, 2025
May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ( …
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
GlobeNewswire
·
May 22, 2025
Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time …
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia
GlobeNewswire
·
May 22, 2025
NEWPORT BEACH, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of a Phase I strategic research …
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
GlobeNewswire
·
May 22, 2025
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa., May …
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
GlobeNewswire
·
May 22, 2025
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data to aggressively pursue novel drug discovery, biomarker …
MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June
GlobeNewswire
·
May 22, 2025
TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its …
LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®
GlobeNewswire
·
May 22, 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes …
SCIENTURE Announces Executive Leadership Transition
GlobeNewswire
·
May 22, 2025
TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025
GlobeNewswire
·
May 22, 2025
Innovative Eclipsys® platform enables rational design of novel Targeted Glues™ with superior drug-like properties Cambridge, UK, 22 May 2025 – Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) …
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
GlobeNewswire
·
May 22, 2025
Daix, May 22, 2025 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program approved …
Descriptif du Programme de Rachat d’Actions Pouvant Être Mis en Œuvre dans le Cadre du Contrat de Liquidité Conclu avec Kepler Chevreux
GlobeNewswire
·
May 22, 2025
Daix, le 22 mai 2025 En application de l'article 241-2 du Règlement Général de l’Autorité des marchés financiers (AMF), le présent descriptif a pour finalité de présenter les objectifs ainsi que les modalités du programme de rachat d’actions autorisé par l …
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 22, 2025
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate …
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
GlobeNewswire
·
May 22, 2025
Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week …